Starting HAART: Should 500 Become the New 350?
Mari Kitahata, M.D., and Daniel Kuritzkes, M.D., discuss a 5,926-patient trial that found a 74% higher mortality risk among those who deferred HAART until their CD4 dropped below 350 rather than initiating when their CD4 was between 351 and 500. Dr. Kuritzkes also touches on new developments in HIV drug resistance.
Conference Highlights: New Studies on New (and Not Quite as New) HIV Meds (Posted Oct. 27, 2008)
From Lexiva to Reyataz and from Prezista to Isentress, several clinical trials were presented at ICAAC/IDSA 2008 that showed promising results for our more recently approved HIV medications. Eric Daar, M.D., gives us the lowdown on these studies and how they may change the HIV treatment landscape.
96-Week ARTEMIS Data Indicate Darunavir Is Superior to Lopinavir in Naive Patients (Posted Oct. 26, 2008)
Following 48-week data that proved darunavir's non-inferiority to lopinavir, these new, even more encouraging 96-week data appear likely to solidify the drug's role in first-line therapy. (An interview with Tony Mills, M.D.)
Crafting First-Line Regimens: So Easy a General Practitioner Could Do It? (Posted Oct. 26, 2008)
We may have more antiretrovirals to choose from than ever before, but selecting an initial HAART regimen today is often a choice between just two regimens, a new study indicates. The findings suggest it may be realistic for primary care physicians and general practitioners to shoulder more of the HIV care burden. (An interview with James McKinnell, M.D.)
Starting HAART: Should 500 Become the New 350? (Posted Oct. 26, 2008)
Mari Kitahata, M.D., and Daniel Kuritzkes, M.D., discuss a 5,926-patient trial that found a 74% higher mortality risk among those who deferred HAART until their CD4 dropped below 350 rather than initiating when their CD4 was between 351 and 500. Dr. Kuritzkes also touches on new developments in HIV drug resistance.
Trend Toward Fewer AIDS-Defining Conditions Among Patients Receiving Raltegravir vs. Placebo (Posted Oct. 26, 2008)
A new examination of 48-week BENCHMRK data found a nearly twofold reduction in AIDS-defining events among patients on raltegravir, but the findings failed to reach statistical significance. Intriguingly, greater resistance did not appear to be a predictor of AIDS-defining events. (An interview with Joseph Eron Jr., M.D.)
The Body PRO's coverage of The 48th Annual ICAAC/IDSA 46th Annual Meeting will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.
For more information on The 48th Annual ICAAC/IDSA 46th Annual Meeting, please visit the conference's Web site. You may also view the conference program online.
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
E-Mail
Glossary
Share
